Opendata, web and dolomites

Genome Biologics

Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry

Total Cost €


EC-Contrib. €






Project "Genome Biologics" data sheet

The following table provides information about the project.


Organization address
address: DANZIGER WEG 17
postcode: 61476
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2017-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOME BIOLOGICS UG DE (KRONBERG IM TAUNUS) coordinator 50˙000.00


 Project objective

Genome Biologics’ novel drug discovery platform addresses the inefficiencies in pre-clinical studies with a unique combination of genomics, molecular science and big data analytics. Using patented single cell transgenic technology, the platform can express 50 different genes in a single animal in 6-8 weeks. This breakthrough approach reduces pre-clinical study time and costs by a factor of 10x, allowing pharmaceuticals companies to bring drug candidates to the stage of human trials in 3-6 months instead of 7-10 years. This drastic cost and time reduction will make it economically possible for pharmaceutical companies to bring affordable and effective treatments for rare diseases, as well as (non-orphan) non-communicable diseases, such as cardiovascular diseases, cancers, chronic respiratory diseases and diabetes, which carry an increasing burden for healthcare systems treating an ageing population. The novel platform also brings a step-change in transgenic animal models: 50-100x less animals are required to generate a reliable model, which reduces drastically the number of animals required in pre-clinical studies and the related ethical burden for pharmaceuticals companies. The solution uses a patent protected DNA/RNA adeno-associated virus technology that enables testing of up to 50 disease-related genes in a target tissue of interest simultaneously, while at the same time ensuring that each of the cells expresses only a single gene. The technology is addressing a market where pharmaceutical companies currently spend €1Bn per year on animal models. We will interview 40 target customers in phase 1 in order to validate the market potential of the solution, and confirm our initial willingness to pay analysis. We will also identify technical improvement areas and define a go to market plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GENOME BIOLOGICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GENOME BIOLOGICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More